Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FIRST ON FOX: A recent study shows that the opioid crisis under the Biden administration has cost the United States a staggering $2.7 trillion in 2023 alone. The study was exclusively obtained by Fox News Digital and released by the Council of Economic Advisers, a policymaking agency within the executive office.
This comprehensive report analyzes the multifaceted impact of the opioid epidemic, attributing costs to various factors such as the loss of life, reduced quality of life, decreased labor productivity, crime-related expenses, and healthcare costs.
The opioid crisis, primarily exacerbated by the synthetic drug fentanyl, has afflicted the U.S. for years. Fentanyl typically originates from China and crosses the U.S. border via Mexico, intensifying the urgency of drug control measures.
In tackling this issue, former President Donald Trump implemented tariffs on goods imported from Canada, Mexico, and China, citing a commitment to enhance border security. Critics of these tariffs argue they may lead to price increases for American consumers. However, the study published by the Council of Economic Advisers suggests that the financial impact of the opioid epidemic significantly outweighs these potential costs.
The study highlights that the costs associated with the opioid crisis nearly double the estimates of the economic effects of Trump’s tariffs. Specifically, the loss of human life in 2023 alone accounted for $1.11 trillion. This figure was calculated by multiplying the number of opioid-related deaths—totaling 74,702 that year—by the value of statistical life in the U.S.
Furthermore, another $1.34 trillion represents the loss of quality of life for individuals suffering from opioid addiction, compared to their healthier counterparts. The study reveals that a person battling opioid use disorder (OUD) experiences about 60% of the quality of life of those without such disorders.
Besides direct health costs, the opioid crisis burdened the U.S. healthcare system with approximately $107 billion in additional expenses linked to treating individuals with OUD. These costs primarily affected private insurers, Medicaid, and hospitals, ultimately increasing financial pressures on all Americans through higher insurance premiums and taxes.
Additionally, the report noted a loss in labor productivity due to the opioid crisis, which also equated to about $107 billion. This figure reflects the number of productive work hours lost as a result of opioid-related deaths, addiction, and incarceration.
The study also addressed the financial strain caused by opioid-related crimes, estimating that policing, legal proceedings, and correctional facilities incurred about $63 billion in costs associated with the epidemic. This financial burden underscores the extensive consequences of the opioid crisis on the wider economy.
The economic toll of the opioid crisis, estimated at $2.7 trillion for just one year, emphasizes the pressing need for strategies to combat the influx of harmful substances entering the country. The ongoing human suffering and financial challenges posed by this epidemic call for immediate and effective action.
Trump’s administration has pursued a stringent border security agenda, with various law enforcement agencies engaging in operations aimed at curbing illegal immigration and drug trafficking. In January, Trump proposed escalating tariffs on imports from Mexico and Canada while also applying levies on Chinese goods, aiming to curb the flow of drugs like fentanyl into the United States.
Despite criticism regarding the potential economic repercussions of these tariffs, including rising consumer costs for everyday goods, the Council of Economic Advisers maintains that the opioid epidemic’s financial impact far surpasses these tariff-related estimates.
Past studies corroborate this trend: a report from 2019 stated the opioid crisis cost the U.S. $2.5 trillion from 2015 to 2018. The new study expands upon this data, considering decreased quality of life and rising overdose rates.
The voice of urgency rings clear in this latest study. To protect public health and preserve economic stability in the U.S., decisive measures must be taken to mitigate the crisis surrounding opioids and fentanyl. The President’s strategies must adapt, ensuring that comprehensive approaches effectively address both the roots and consequences of this significant public health challenge.
The crisis underscores an essential truth: the financial costs of inaction are far greater than the sacrifices made to ensure a safer, healthier America.